Summary & Overview
HCPCS Q5160: Bevacizumab-nwgd (Jobevne) 10 mg Injection
HCPCS Level II code Q5160 designates a 10 mg unit of bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab used in oncology and select ophthalmology indications when appropriate. The code identifies the biologic product and strength for billing of the injected medication and is relevant across outpatient infusion settings nationally because biologic therapies drive significant drug spend and have evolving coverage policies.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for bevacizumab biosimilars, the typical sites of service where Q5160 is billed, and what national payers commonly consider when covering biosimilar oncology agents. The briefing outlines the types of benchmarks and policy elements typically reviewed for this code, including billing units, infusion administration context, and product-specific coverage considerations.
This summary supports stakeholders—hospital administrators, billing professionals, and policy analysts—in understanding where Q5160 fits into the drug billing landscape, what payer coverage alignment to expect, and which operational and policy levers are most relevant when managing biosimilar bevacizumab use in outpatient infusion environments.
Billing Code Overview
HCPCS Level II code Q5160 represents an injection of bevacizumab-nwgd (Jobevne), biosimilar, 10 mg. This entry denotes the specific biologic product and strength for administration of bevacizumab offered as a biosimilar.
Service type: Intravenous biologic infusion/injection medication administration
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old with metastatic colorectal carcinoma or recurrent epithelial ovarian cancer receiving systemic targeted therapy. The patient presents to an outpatient oncology infusion center for administration of bevacizumab biosimilar (Q5160, 10 mg vial). Pre-infusion nursing assessment includes vital signs, review of recent labs (especially CBC, CMP, urine protein), allergy check, and confirmation of prior imaging and oncologist orders. Pharmacy compounds the appropriate dose using one or more Q5160 vials based on calculated weight-based dosing (commonly 5–15 mg/kg depending on regimen) and performs aseptic technique and labeling. An oncology RN initiates IV access, administers the pre-medications if required, and infuses the bevacizumab biosimilar per protocol with monitoring for infusion reactions, hypertension, proteinuria, thromboembolic events, gastrointestinal perforation risk, and wound-healing complications. Post-infusion updates are documented, and the patient is instructed on signs/symptoms that require urgent evaluation. Typical sites of service are outpatient hospital infusion centers or physician office infusion suites where parenteral biologic oncology drugs are administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient |